<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026493</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG-0929</org_study_id>
    <secondary_id>CDR0000660545</secondary_id>
    <nct_id>NCT01026493</nct_id>
  </id_info>
  <brief_title>Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma</brief_title>
  <official_title>A Randomized Phase I/II Study of ABT-888 in Combination With Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Veliparib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth. Drugs used in chemotherapy, such as temozolomide. work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Giving veliparib together with temozolomide may kill more tumor cells.

      PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of
      giving veliparib together with temozolomide and to see how well it works in treating patients
      with recurrent glioblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To define the maximum-tolerated dose of the combination of temozolomide and veliparib in
           patients with recurrent glioblastoma previously or not treated with temozolomide. (Phase
           I*)

        -  To determine the efficacy of the combination of temozolomide and veliparib (using a
           5-day vs 21-day schedule) as measured by the 6-month progression-free survival rate in
           patients with recurrent glioblastoma previously treated with temozolomide. (Phase II*)

      Secondary

        -  To characterize the safety profile of the combination of temozolomide and veliparib.
           (Phase I*)

        -  To determine the adverse event profile and tolerability of the combination of
           temozolomide and veliparib (using a 5-day vs 21-day schedule) in patients with recurrent
           glioblastoma. (Phase II*)

        -  To determine the efficacy of the combination of temozolomide and veliparib (using a
           5-day vs 21-day schedule) as measured by objective response in patients with measurable
           disease. (Phase II*)

        -  To determine the overall survival of patients treated with the combination of
           temozolomide and veliparib (using a 5-day vs 21-day schedule). (Phase II*) Note: *Phase
           I was closed and phase II was opened on 3/6/12.

      OUTLINE: This is a multicenter, phase I* dose-escalation study followed by a phase II*
      randomized study. Patients enrolled in the phase II portion are stratified according to
      bevacizumab (BEV) status (bevacizumab-naive vs bevacizumab-failure), age (&lt; 50 years vs ≥ 50
      years), Karnofsky performance status (70-80% vs 90-100%), and recent resection (yes vs
      no/biopsy only).

        -  Phase I:* Patients receive oral temozolomide once daily and oral veliparib twice daily
           on days 1-21. Courses repeat every 28 days in the absence of disease progression or
           unacceptable toxicity.

        -  Phase II:* Patients are randomized to 1 of 2 treatment arms.

             -  Arm I: Patients receive temozolomide and veliparib as in phase I.

             -  Arm II: Patients receive oral temozolomide once daily and oral veliparib twice
                daily on days 1-5. Courses repeat every 28 days in the absence of disease
                progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 12 weeks for 1 year,
      every 26 weeks for 2 years, and then annually thereafter.

      Note: *Phase I was closed and phase II was opened on 3/6/12.

      PROJECTED ACCRUAL: A total of 240 patients (28 for phase I* and 212 for phase II*) will be
      accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Start of treatment to 8 weeks.</time_frame>
    <description>Dose limiting toxicity (DLT) = any of the following events within 1st 8 weeks of treatment attributable to study drugs: Any grade (gr) 3/4 thrombocytopenia, gr 4 anemia, gr 3 neutropenia with fever (&gt;100.4). gr 4 neutropenia lasting &gt; 7 days; Any non-hematologic (NH) gr 3+ toxicity (TOX), excluding alopecia, despite maximal medical therapy (MLT); NH TOX such as rash, nausea, vomiting, diarrhea, mucositis, hypophosphatemia, and hypertension will only be considered DLTs if they remain gr 3+ despite MLT; 2nd occurrence of thromboembolism; Failure to recover from TOX (&lt;= gr 1) to be eligible for re-treatment with study drugs &lt;= 14 days of last dose of either drug; Any episode of non-infectious radiologically observed pneumonitis gr 2-4 any duration. Dose level will be considered acceptable if &lt;= 1 of the 1st 6 eligible patients experiences a DLT. If current level is considered acceptable, dose escalation occurs. Otherwise preceding acceptable dose level will be declared the MTD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: 6-month Progression-free Survival (PFS) Rate for Patients With Measurable Disease After Surgery</measure>
    <time_frame>Randomization to 6 months.</time_frame>
    <description>For patients with measureable disease after surgery: Progression defined as ≥ 25% increase in size of enhancing tumor or any new tumor; or neurologically worse, and steroids stable/increased. Bevacizumab (BEV)-naïve group: p0= 15% as estimate of 6-mo. PFS [null hypothesis (NH)], p1= 30%, with a 15% absolute increase [alternative hypothesis (AH)]. Error rates of 10% alpha and 10% beta. If &lt;= 11 patients experience 6-month PFS of the first 53 analyzable patients, then do not reject the null hypothesis that the 6-month PFS rate of experimental arm is less than 15%; BEV-failure group: p0 = 2% as a conservative estimate of 6-month PFS [NH], p1 = 15%, with a 13% absolute increase [AH]. Using first 26 analyzable subjects for each experimental arm, there is &gt;= 90% power to detect &gt;= 15% increase at a significance level of 0.10, using a 1-sided binomial test. If &gt;= 2 patients (8%) are progression free at 6 mo., then claim this regimen to be promising in the patient group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II: Objective Response (Partial and Complete Response) Rate for Patients With Measurable Disease After Surgery</measure>
    <time_frame>Analysis occurs after all patients have been on study for at 6 months. (Patients are followed from randomization to death or study termination whichever occurs first.)</time_frame>
    <description>Response and progression will be evaluated using standard criteria for patients with malignant gliomas (Macdonald 1990). Partial response and complete response are centrally reviewed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Overall Survival (OS)</measure>
    <time_frame>Analysis occurs after all patients have been on study for at 6 months. (Patients are followed from randomization to death or study termination whichever occurs first.)</time_frame>
    <description>Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. This analysis was planned to occur when all patients had been potentially followed for at least 6 months.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">257</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Phase I: Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-888 20 mg x 21 days plus temozolomide 60 mg x 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: Dose Level 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-888 40 mg x 21 days plus temozolomide 60 mg x 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: Dose Level 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-888 20 mg x 21 days plus temozolomide 75 mg x 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Arm 1/BEV-NAIVE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Arm 2/BEV-NAIVE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Arm 1/BEV-FAILURE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Arm 2/BEV-FAILURE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide 60 mg x 21 days</intervention_name>
    <description>Temozolomide 60 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.</description>
    <arm_group_label>Phase I: Dose Level 1</arm_group_label>
    <arm_group_label>Phase I: Dose Level 2a</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>Temodal</other_name>
    <other_name>Temcad</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide 75 mg x 21 days</intervention_name>
    <description>Temozolomide 75 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.</description>
    <arm_group_label>Phase I: Dose Level 2b</arm_group_label>
    <arm_group_label>Phase I: Dose Level 3</arm_group_label>
    <arm_group_label>Phase II: Arm 1/BEV-NAIVE</arm_group_label>
    <arm_group_label>Phase II: Arm 1/BEV-FAILURE</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>Temodal</other_name>
    <other_name>Temcad</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-888 20 mg x 21 days</intervention_name>
    <description>20 mg bid x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.</description>
    <arm_group_label>Phase I: Dose Level 1</arm_group_label>
    <arm_group_label>Phase I: Dose Level 2b</arm_group_label>
    <other_name>Veliparib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-888 40 mg x 21 days</intervention_name>
    <description>40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy</description>
    <arm_group_label>Phase I: Dose Level 2a</arm_group_label>
    <arm_group_label>Phase I: Dose Level 3</arm_group_label>
    <arm_group_label>Phase II: Arm 1/BEV-NAIVE</arm_group_label>
    <arm_group_label>Phase II: Arm 1/BEV-FAILURE</arm_group_label>
    <other_name>Veliparib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide 150 mg x 5 days</intervention_name>
    <description>150 mg/m2 x 5 days (up to 200 mg/m2 after 2nd cycle)*, with a 28-day cycle; dose reduction to 125 mg/m2 if necessary. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude</description>
    <arm_group_label>Phase II: Arm 2/BEV-NAIVE</arm_group_label>
    <arm_group_label>Phase II: Arm 2/BEV-FAILURE</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>Temcad</other_name>
    <other_name>Temodal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-888 40 mg x 5 days</intervention_name>
    <description>40 mg bid x 5 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude</description>
    <arm_group_label>Phase II: Arm 2/BEV-NAIVE</arm_group_label>
    <arm_group_label>Phase II: Arm 2/BEV-FAILURE</arm_group_label>
    <other_name>Veliparib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of 1 of the following:

               -  Any intracranial high-grade glioma (phase I*)

               -  Glioblastoma or gliosarcoma (phase II*)

          -  Patients whose original histology was low-grade glioma are eligible provided they were
             subsequently diagnosed with glioblastoma or gliosarcoma

          -  Unequivocal radiographic evidence for tumor progression by MRI within 14 days prior to
             registration and with a stable or decreasing dose of steroids at least 5 days prior to
             scanning OR recent resection (registration within 30 days of resection) as long as all
             of the following conditions are met:

               -  Patients must have recovered from the effects of surgery

               -  Residual disease following resection of recurrent glioblastoma is not mandated
                  for eligibility into the study; to best assess the extent of residual disease
                  post-operatively, a post-operative MRI scan should be performed within 28 days
                  prior to registration and within 96 hours post surgery (although 24 hours would
                  be optimum)

               -  Prior radiation is required for the phase I* arm

               -  Patients must have completed a course of radiation therapy and at least 2
                  consecutive adjuvant cycles of temozolomide (phase II*)

               -  A stable or decreasing dose of steroids at least 5 days prior to scanning is not
                  mandated for patients who had a recent resection

          -  No evidence of acute (i.e., new and active) intratumoral hemorrhage on MRI

               -  Patients with MRI demonstrating old hemorrhage or subacute blood after a
                  neurosurgical procedure (biopsy or resection) are eligible Note: *Phase I was
                  closed and phase II was opened on 3/6/12.

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 70-100%

          -  White blood cell (WBC) count ≥ 3,000/mm^3

          -  Absolute neutrophil count (ANC) ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 10.0 g/dL (transfusion or other intervention allowed)

          -  Serum glutamic oxaloacetic transaminase (SGOT) ≤ 3.0 times upper limit of normal (ULN)

          -  Serum glutamic pyruvic transaminase (SGPT) ≤ 3.0 times ULN

          -  Bilirubin ≤ 1.25 times ULN

          -  Creatinine &lt; 1.7 mg/dL OR estimated glomerular filtration rate (GFR) ≥ 30 mL/min

          -  Urine protein:creatinine ratio ≤ 0.5 OR urine protein &lt; 1,000 mg by 24-hour urine
             collection**

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for ≥ 6 months after
             completion of study therapy

          -  Able to undergo brain MRI scans with IV gadolinium

          -  Able to swallow oral medications

          -  Patients with a history of seizure, or new onset of seizures, should be clinically
             controlled with no seizures for at least 14 days prior to registration

          -  No other prior invasive malignancy (except for nonmelanomatous skin cancer or
             carcinoma in situ of the cervix) unless the patient has been disease-free and off
             therapy for that disease for ≥ 3 years

          -  No severe, active comorbidity, including any of the following:

               -  Transmural myocardial infarction or unstable angina within the past 6 months

               -  Evidence of recent myocardial infarction or ischemia as indicated by S-T
                  elevations of ≥ 2 mm on EKG performed within the past 14 days

               -  New York Heart Association (NYHA) class II-IV congestive heart failure requiring
                  hospitalization within the past 12 months

               -  Stroke or transient ischemic attack within the past 6 months

               -  Cerebral vascular accident within the past 6 months

               -  Serious and inadequately controlled cardiac arrhythmia

               -  Clinically significant peripheral vascular disease

               -  Evidence of bleeding diathesis or coagulopathy

               -  Serious non-healing would, ulcer, or bone fracture

               -  Abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess
                  within the past 28 days

               -  Significant traumatic injury within the past 28 days

               -  Acute bacterial or fungal infection requiring IV antibiotics at the time of study
                  registration

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy within the past 14 days

               -  AIDS based upon current Centers for Disease Control and Prevention (CDC)
                  definition (HIV testing is not required)

          -  No condition that would impair the ability to swallow pills (e.g., GI tract disease
             resulting in an inability to take oral medication or a requirement for IV
             alimentation, prior surgical procedures affecting absorption, or active peptic ulcer
             disease)

          -  No disease that would obscure toxicity or dangerously alter drug metabolism

          -  Not on dialysis

          -  No history of chronic hepatitis B or C Note: **Required for patients who received
             prior bevacizumab and developed known clinically significant nephrotic syndrome during
             treatment and whose baseline values have not returned to normal.

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from the toxic effects of prior therapy

          -  Prior interstitial brachytherapy, Gliadel wafer, or stereotactic radiosurgery allowed
             provided there is confirmation of progressive disease by positron emission tomography
             (PET) scan, thallium scan, MRI spectroscopy, perfusion MRI, or surgical documentation

          -  No more than 3 prior treatment regimens (phase I*)

          -  No more than 2 prior treatment regimens for recurrent glioblastoma/gliosarcoma (phase
             II*)

          -  More than 28 days since prior major surgical procedure or open biopsy (with the
             exception of craniotomy)

          -  At least 28 days since prior investigational agents or cytotoxic agents (42 days for
             nitrosoureas, 21 days for procarbazine, and 14 days for vincristine)

          -  At least 14 days since prior non-cytotoxic agents (e.g., bevacizumab, interferon,
             tamoxifen, thalidomide, isotretinoin, or tyrosine kinase inhibitors)

          -  No concurrent highly-active antiretroviral therapy

          -  No concurrent herbal products of unknown constitution

          -  No concurrent major surgical procedures Note: *Phase I was closed and phase II was
             opened on 3/6/12.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Ian Robins, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark R Gilbert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute/National Institutes of Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnab Chakravarti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, Ohio State University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rebecca and John Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeward Radiation Oncology</name>
      <address>
        <city>'Ewa Beach</city>
        <state>Hawaii</state>
        <zip>96706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Center of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Cancer Institute at Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawaii Medical Center - East</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kansas City</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Baptist Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503-9985</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisville Oncology at Norton Cancer Institute - Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Center at Singing River Hospital</name>
      <address>
        <city>Pascagoula</city>
        <state>Mississippi</state>
        <zip>39581</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renown Institute for Cancer at Renown Regional Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highland Hospital of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Good Samaritan Hospital &amp; Comprehensive Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <results_first_submitted>January 17, 2017</results_first_submitted>
  <results_first_submitted_qc>June 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2017</results_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult pineal gland astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phase I: Dose Level 1</title>
          <description>ABT-888 20 mg x 21 days plus temozolomide 60 mg x 21 days</description>
        </group>
        <group group_id="P2">
          <title>Phase I: Dose Level 2a</title>
          <description>ABT-888 40 mg x 21 days plus temozolomide 60 mg x 21 days</description>
        </group>
        <group group_id="P3">
          <title>Phase I: Dose Level 2b</title>
          <description>ABT-888 20 mg x 21 days plus temozolomide 75 mg x 21 days</description>
        </group>
        <group group_id="P4">
          <title>Phase I: Dose Level 3</title>
          <description>ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days</description>
        </group>
        <group group_id="P5">
          <title>Phase II: Arm 1/BEV-NAIVE</title>
          <description>ABT-888 40 mg x 5 days plus temozolomide 75 mg x 5 days</description>
        </group>
        <group group_id="P6">
          <title>Phase II: Arm 2/BEV-NAIVE</title>
          <description>ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days</description>
        </group>
        <group group_id="P7">
          <title>Phase II: Arm 1/BEV-FAILURE</title>
          <description>ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days</description>
        </group>
        <group group_id="P8">
          <title>Phase II: Arm 2/BEV-FAILURE</title>
          <description>ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8">Subjects with data available for the primary analysis are considered to have completed the study.</participants>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="75"/>
                <participants group_id="P6" count="76"/>
                <participants group_id="P7" count="36"/>
                <participants group_id="P8" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="73"/>
                <participants group_id="P6" count="73"/>
                <participants group_id="P7" count="32"/>
                <participants group_id="P8" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eligible patients</population>
      <group_list>
        <group group_id="B1">
          <title>Phase I: Dose Level 1</title>
          <description>ABT-888 20 mg x 21 days plus temozolomide 60 mg x 21 days</description>
        </group>
        <group group_id="B2">
          <title>Phase I: Dose Level 2a</title>
          <description>ABT-888 40 mg x 21 days plus temozolomide 60 mg x 21 days</description>
        </group>
        <group group_id="B3">
          <title>Phase I: Dose Level 2b</title>
          <description>ABT-888 20 mg x 21 days plus temozolomide 75 mg x 21 days</description>
        </group>
        <group group_id="B4">
          <title>Phase I: Dose Level 3</title>
          <description>ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days</description>
        </group>
        <group group_id="B5">
          <title>Phase II: Arm 1/BEV-NAIVE</title>
          <description>ABT-888 40 mg x 5 days plus temozolomide 75 mg x 5 days</description>
        </group>
        <group group_id="B6">
          <title>Phase II: Arm 2/BEV-NAIVE</title>
          <description>ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days</description>
        </group>
        <group group_id="B7">
          <title>Phase II: Arm 1/BEV-FAILURE</title>
          <description>ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days</description>
        </group>
        <group group_id="B8">
          <title>Phase II: Arm 2/BEV-FAILURE</title>
          <description>ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="73"/>
            <count group_id="B6" value="73"/>
            <count group_id="B7" value="32"/>
            <count group_id="B8" value="37"/>
            <count group_id="B9" value="246"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="20" upper_limit="63"/>
                    <measurement group_id="B2" value="51" lower_limit="48" upper_limit="63"/>
                    <measurement group_id="B3" value="53" lower_limit="18" upper_limit="67"/>
                    <measurement group_id="B4" value="41" lower_limit="20" upper_limit="81"/>
                    <measurement group_id="B5" value="56" lower_limit="21" upper_limit="77"/>
                    <measurement group_id="B6" value="56" lower_limit="20" upper_limit="81"/>
                    <measurement group_id="B7" value="56" lower_limit="20" upper_limit="70"/>
                    <measurement group_id="B8" value="57" lower_limit="38" upper_limit="77"/>
                    <measurement group_id="B9" value="56" lower_limit="18" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="47"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="23"/>
                    <measurement group_id="B9" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase 1: Maximum Tolerated Dose (MTD)</title>
        <description>Dose limiting toxicity (DLT) = any of the following events within 1st 8 weeks of treatment attributable to study drugs: Any grade (gr) 3/4 thrombocytopenia, gr 4 anemia, gr 3 neutropenia with fever (&gt;100.4). gr 4 neutropenia lasting &gt; 7 days; Any non-hematologic (NH) gr 3+ toxicity (TOX), excluding alopecia, despite maximal medical therapy (MLT); NH TOX such as rash, nausea, vomiting, diarrhea, mucositis, hypophosphatemia, and hypertension will only be considered DLTs if they remain gr 3+ despite MLT; 2nd occurrence of thromboembolism; Failure to recover from TOX (&lt;= gr 1) to be eligible for re-treatment with study drugs &lt;= 14 days of last dose of either drug; Any episode of non-infectious radiologically observed pneumonitis gr 2-4 any duration. Dose level will be considered acceptable if &lt;= 1 of the 1st 6 eligible patients experiences a DLT. If current level is considered acceptable, dose escalation occurs. Otherwise preceding acceptable dose level will be declared the MTD.</description>
        <time_frame>Start of treatment to 8 weeks.</time_frame>
        <population>Eligible patients who started study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I: Dose Level 1</title>
            <description>ABT-888 20 mg x 21 days plus temozolomide 60 mg x 21 days</description>
          </group>
          <group group_id="O2">
            <title>Phase I: Dose Level 2a</title>
            <description>ABT-888 40 mg x 21 days plus temozolomide 60 mg x 21 days</description>
          </group>
          <group group_id="O3">
            <title>Phase I: Dose Level 2b</title>
            <description>ABT-888 20 mg x 21 days plus temozolomide 75 mg x 21 days</description>
          </group>
          <group group_id="O4">
            <title>Phase I: Dose Level 3</title>
            <description>ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Maximum Tolerated Dose (MTD)</title>
          <description>Dose limiting toxicity (DLT) = any of the following events within 1st 8 weeks of treatment attributable to study drugs: Any grade (gr) 3/4 thrombocytopenia, gr 4 anemia, gr 3 neutropenia with fever (&gt;100.4). gr 4 neutropenia lasting &gt; 7 days; Any non-hematologic (NH) gr 3+ toxicity (TOX), excluding alopecia, despite maximal medical therapy (MLT); NH TOX such as rash, nausea, vomiting, diarrhea, mucositis, hypophosphatemia, and hypertension will only be considered DLTs if they remain gr 3+ despite MLT; 2nd occurrence of thromboembolism; Failure to recover from TOX (&lt;= gr 1) to be eligible for re-treatment with study drugs &lt;= 14 days of last dose of either drug; Any episode of non-infectious radiologically observed pneumonitis gr 2-4 any duration. Dose level will be considered acceptable if &lt;= 1 of the 1st 6 eligible patients experiences a DLT. If current level is considered acceptable, dose escalation occurs. Otherwise preceding acceptable dose level will be declared the MTD.</description>
          <population>Eligible patients who started study treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase II: 6-month Progression-free Survival (PFS) Rate for Patients With Measurable Disease After Surgery</title>
        <description>For patients with measureable disease after surgery: Progression defined as ≥ 25% increase in size of enhancing tumor or any new tumor; or neurologically worse, and steroids stable/increased. Bevacizumab (BEV)-naïve group: p0= 15% as estimate of 6-mo. PFS [null hypothesis (NH)], p1= 30%, with a 15% absolute increase [alternative hypothesis (AH)]. Error rates of 10% alpha and 10% beta. If &lt;= 11 patients experience 6-month PFS of the first 53 analyzable patients, then do not reject the null hypothesis that the 6-month PFS rate of experimental arm is less than 15%; BEV-failure group: p0 = 2% as a conservative estimate of 6-month PFS [NH], p1 = 15%, with a 13% absolute increase [AH]. Using first 26 analyzable subjects for each experimental arm, there is &gt;= 90% power to detect &gt;= 15% increase at a significance level of 0.10, using a 1-sided binomial test. If &gt;= 2 patients (8%) are progression free at 6 mo., then claim this regimen to be promising in the patient group.</description>
        <time_frame>Randomization to 6 months.</time_frame>
        <population>Randomized patients with measurable disease after surgery, at least one cycle of treatment, evaluable for 6 month PFS, and within the required sample size (i.e. the first 53 BEV-naive patients and the first 26 BEV-failure patients- the number of patients will be less than sample size if not enough patients meet the criteria).</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II: Arm 1/BEV-NAIVE</title>
            <description>ABT-888 40 mg x 5 days plus temozolomide 75 mg x 5 days</description>
          </group>
          <group group_id="O2">
            <title>Phase II: Arm 2/BEV-NAIVE</title>
            <description>ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days</description>
          </group>
          <group group_id="O3">
            <title>Phase II: Arm 1/BEV-FAILURE</title>
            <description>ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days</description>
          </group>
          <group group_id="O4">
            <title>Phase II: Arm 2/BEV-FAILURE</title>
            <description>ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: 6-month Progression-free Survival (PFS) Rate for Patients With Measurable Disease After Surgery</title>
          <description>For patients with measureable disease after surgery: Progression defined as ≥ 25% increase in size of enhancing tumor or any new tumor; or neurologically worse, and steroids stable/increased. Bevacizumab (BEV)-naïve group: p0= 15% as estimate of 6-mo. PFS [null hypothesis (NH)], p1= 30%, with a 15% absolute increase [alternative hypothesis (AH)]. Error rates of 10% alpha and 10% beta. If &lt;= 11 patients experience 6-month PFS of the first 53 analyzable patients, then do not reject the null hypothesis that the 6-month PFS rate of experimental arm is less than 15%; BEV-failure group: p0 = 2% as a conservative estimate of 6-month PFS [NH], p1 = 15%, with a 13% absolute increase [AH]. Using first 26 analyzable subjects for each experimental arm, there is &gt;= 90% power to detect &gt;= 15% increase at a significance level of 0.10, using a 1-sided binomial test. If &gt;= 2 patients (8%) are progression free at 6 mo., then claim this regimen to be promising in the patient group.</description>
          <population>Randomized patients with measurable disease after surgery, at least one cycle of treatment, evaluable for 6 month PFS, and within the required sample size (i.e. the first 53 BEV-naive patients and the first 26 BEV-failure patients- the number of patients will be less than sample size if not enough patients meet the criteria).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Objective Response (Partial and Complete Response) Rate for Patients With Measurable Disease After Surgery</title>
        <description>Response and progression will be evaluated using standard criteria for patients with malignant gliomas (Macdonald 1990). Partial response and complete response are centrally reviewed.</description>
        <time_frame>Analysis occurs after all patients have been on study for at 6 months. (Patients are followed from randomization to death or study termination whichever occurs first.)</time_frame>
        <population>Eligible patients with at least one cycle of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II: Arm 1/BEV-NAIVE</title>
            <description>ABT-888 40 mg x 5 days plus temozolomide 75 mg x 5 days</description>
          </group>
          <group group_id="O2">
            <title>Phase II: Arm 2/BEV-NAIVE</title>
            <description>ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days</description>
          </group>
          <group group_id="O3">
            <title>Phase II: Arm 1/BEV-FAILURE</title>
            <description>ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days</description>
          </group>
          <group group_id="O4">
            <title>Phase II: Arm 2/BEV-FAILURE</title>
            <description>ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Objective Response (Partial and Complete Response) Rate for Patients With Measurable Disease After Surgery</title>
          <description>Response and progression will be evaluated using standard criteria for patients with malignant gliomas (Macdonald 1990). Partial response and complete response are centrally reviewed.</description>
          <population>Eligible patients with at least one cycle of treatment</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="3.8" lower_limit="0" upper_limit="8.9"/>
                    <measurement group_id="O3" value="5.3" lower_limit="0" upper_limit="15.3"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Overall Survival (OS)</title>
        <description>Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. This analysis was planned to occur when all patients had been potentially followed for at least 6 months.</description>
        <time_frame>Analysis occurs after all patients have been on study for at 6 months. (Patients are followed from randomization to death or study termination whichever occurs first.)</time_frame>
        <population>Eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II: Arm 1/BEV-NAIVE</title>
            <description>ABT-888 40 mg x 5 days plus temozolomide 75 mg x 5 days</description>
          </group>
          <group group_id="O2">
            <title>Phase II: Arm 2/BEV-NAIVE</title>
            <description>ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days</description>
          </group>
          <group group_id="O3">
            <title>Phase II: Arm 1/BEV-FAILURE</title>
            <description>ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days</description>
          </group>
          <group group_id="O4">
            <title>Phase II: Arm 2/BEV-FAILURE</title>
            <description>ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Overall Survival (OS)</title>
          <description>Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. This analysis was planned to occur when all patients had been potentially followed for at least 6 months.</description>
          <population>Eligible patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="7.6" upper_limit="13.4"/>
                    <measurement group_id="O2" value="10.7" lower_limit="7.6" upper_limit="12.6"/>
                    <measurement group_id="O3" value="4.7" lower_limit="3.0" upper_limit="6.3"/>
                    <measurement group_id="O4" value="4.7" lower_limit="3.4" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Log Rank</method>
            <method_desc>Two-sided test</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
            <estimate_desc>Reference level = Arm 1/BEV-NAIVE</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>Log Rank</method>
            <method_desc>Two-sided test</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
            <estimate_desc>Reference level = Arm 1/BEV-FAILURE</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Subjects experiencing more than one of a given adverse event are counted only once for that adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase I: Dose Level 1</title>
          <description>ABT-888 20 mg x 21 days plus temozolomide 60 mg x 21 days</description>
        </group>
        <group group_id="E2">
          <title>Phase I: Dose Level 2a</title>
          <description>ABT-888 40 mg x 21 days plus temozolomide 60 mg x 21 days</description>
        </group>
        <group group_id="E3">
          <title>Phase I: Dose Level 2b</title>
          <description>ABT-888 20 mg x 21 days plus temozolomide 75 mg x 21 days</description>
        </group>
        <group group_id="E4">
          <title>Phase I: Dose Level 3</title>
          <description>ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days</description>
        </group>
        <group group_id="E5">
          <title>Phase II: Arm 1/BEV-NAIVE</title>
          <description>ABT-888 40 mg x 5 days plus temozolomide 75 mg x 5 days</description>
        </group>
        <group group_id="E6">
          <title>Phase II: Arm 2/BEV-NAIVE</title>
          <description>ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days</description>
        </group>
        <group group_id="E7">
          <title>Phase II: Arm 1/BEV-FAILURE</title>
          <description>ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days</description>
        </group>
        <group group_id="E8">
          <title>Phase II: Arm 2/BEV-FAILURE</title>
          <description>ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Muscle weakness left-sided</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Muscle weakness right-sided</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Edema cerebral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Facial muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="70" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="70" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="31" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="32" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="48" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness left-sided</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Urinary tract pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wendy Seiferheld, M.S.</name_or_title>
      <organization>NRG Oncology</organization>
      <email>seiferheldw@nrgoncology.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

